Frazier Life Sciences Management’s Alkermes ALKS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-700,647
Closed -$36.7M – 45
2026
Q2
$36.7M Hold
700,647
– – 0.8% 24
2026
Q1
$24.8M Hold
700,647
– – 0.64% 27
2025
Q4
$19.6M Hold
700,647
– – 0.53% 31
2025
Q3
$21M Sell
700,647
-300,000
-30% -$8.46M 0.63% 29
2025
Q2
$28.6M Buy
1,000,647
+399,518
+66% +$11.9M 1.14% 20
2025
Q1
$19.8M Hold
601,129
– – 0.91% 23
2024
Q4
$17.3M Buy
601,129
+25,000
+4% +$719K 0.72% 29
2024
Q3
$16.1M Buy
+576,129
New +$15.4M 0.65% 33

Other funds holding ALKS

Frazier Life Sciences Management's ALKS Position: Q3 2026 in Review

Frazier Life Sciences Management sold out of Alkermes (ALKS) in Q3 2026, closing a stake of 700,647 shares — an estimated $36.7M sold.

Frazier Life Sciences Management first reported a position in ALKS in Q3 2024 and held it in 8 quarters. The position peaked at $36.7M in Q2 2026. 410 funds tracked by Wall St. Rank hold ALKS as of Q3 2026.

  • Frazier Life Sciences Management reported no remaining Alkermes position as of Q3 2026 after selling out during the quarter.
  • Frazier Life Sciences Management sold 700,647 Alkermes shares in Q3 2026, an estimated $36.7M.
  • Frazier Life Sciences Management first reported a position in Alkermes in Q3 2024 and held it in 8 quarters.
  • Frazier Life Sciences Management's Alkermes position peaked at $36.7M in Q2 2026.
  • 410 funds tracked by Wall St. Rank held Alkermes as of Q3 2026.

Based on Frazier Life Sciences Management's 13F filing for Q3 2026, filed 16 Nov 2026.